- Companies
- Co-Diagnostics
Co-Diagnostics Valuation Multiples
Co-Diagnostics is valued at $7M as of September 2026, a 7.4x revenue multiple. In the last FY Co-Diagnostics reported revenue of $622K and EBITDA of ($48M).
Co-Diagnostics Overview
About Co-Diagnostics
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
Founded
2013
HQ
Employees
115
Website
Financials (LTM)
EV
$5M
Valuation Multiples
Start free trialCo-Diagnostics Financials
Co-Diagnostics reported last 12-month revenue of $645K.
In the same LTM period, Co-Diagnostics generated had net loss of ($34M).
Revenue (LTM)
Co-Diagnostics P&L
In the most recent fiscal year, Co-Diagnostics reported revenue of $622K and EBITDA of ($48M).
Co-Diagnostics is unprofitable as of last fiscal year, with gross margin of 64%, EBITDA margin of (7662%), and net margin of (7534%).
Financial data powered by Morningstar, Inc.
Co-Diagnostics Stock Performance
Co-Diagnostics has current market cap of $7M, and enterprise value of $5M.
Market Cap Evolution
Co-Diagnostics' stock price is $0.95.
Co-Diagnostics share price decreased by 24.3% in the last 30 days, and by 90.8% in the last year.
Co-Diagnostics has an EPS (earnings per share) of $-6.72.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5M | $7M | -0.0% | -24.3% | -69.5% | -90.8% | $-6.72 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCo-Diagnostics Valuation Multiples
Co-Diagnostics trades at 7.4x EV/Revenue multiple, and (0.1x) EV/EBITDA.
EV / Revenue (LTM)
Co-Diagnostics Financial Valuation Multiples
As of September 19, 2026, Co-Diagnostics has market cap of $7M and EV of $5M.
Co-Diagnostics has a P/E ratio of (0.2x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Co-Diagnostics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Co-Diagnostics Margins & Growth Rates
Co-Diagnostics grew revenue by 5% but net profit decreased by 39% in the last fiscal year.
In the most recent fiscal year, Co-Diagnostics reported gross margin of 64%, EBITDA margin of (7662%), and net margin of (7534%).
Co-Diagnostics Margins
Co-Diagnostics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Co-Diagnostics Operational KPIs
Co-Diagnostics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.4M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Co-Diagnostics Competitors
Co-Diagnostics competitors include BibbInstruments, Bio-Gate, PExA, Scandinavian ChemoTech, enVVeno Medical, Sds Optic, Sonendo, Trinity Biotech, Neola Medical and Redsense Medical.
Most Co-Diagnostics public comparables operate across Medical Devices, Laboratory Services, HealthTech and DeepTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $41K | ($1M) | 72.6x | - | (2.2x) | - | |||
| $9M | ($1M) | 0.7x | 0.7x | (5.6x) | (7.5x) | |||
| $49K | ($600K) | 137.7x | - | (11.2x) | - | |||
| $1M | ($457K) | 5.0x | 4.0x | (13.6x) | (19.8x) | |||
| - | ($20M) | - | - | - | - | |||
| $198K | ($306K) | 34.0x | - | (22.0x) | - | |||
| $32M | ($27M) | 0.2x | 0.2x | (0.2x) | - | |||
| $44M | ($22M) | 3.2x | - | (6.4x) | - | |||
This data is available for Pro users. Sign up to see all Co-Diagnostics competitors and their valuation data. Start Free Trial | ||||||||
Acquisitions by Co-Diagnostics
Co-Diagnostics has acquired 3 companies to date.
Last acquisition by Co-Diagnostics was on December 23rd 2021. Co-Diagnostics acquired Idaho Molecular for $21M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Co-Diagnostics
| Description | Idaho Molecular is a Meridian-based biotechnology firm developing diagnostic devices for labs, hospitals, and research facilities. The company produces molecular testing platforms for infectious diseases and genetic analysis, enabling rapid data-driven decisions. Idaho Molecular's solutions integrate PCR technology and cloud-based reporting for clinical applications. | Advanced Conceptions is a medical device company specializing in diagnostic and therapeutic tools for reproductive health. Mountain View, California-based, it develops intrauterine devices and fertility assessment systems to improve conception rates and embryo selection. | MEDCIS Pathlabs India Pvt. Ltd. is a clinical investigation laboratory providing diagnostic services in pathology, biochemistry, microbiology, and histopathology across India. Hyderabad-based, the company integrates global diagnostic technologies to support physician decision-making with accurate test reports in multiple medical branches. |
| HQ Country | |||
| HQ City | Salt Lake City, UT | Salt Lake City, UT | Hyderabad |
| Deal Date | 23 Dec 2021 | 23 Dec 2021 | 5 Sep 2017 |
| Valuation | $21M | $36M | undisclosed |
| EV/Revenue | |||
| EV/EBITDA | |||
This data is available for Pro users. Sign up to see all Co-Diagnostics acquisitions and their M&A valuation multiples. Start Free Trial | |||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Co-Diagnostics
| Who are competitors of Co-Diagnostics? | Co-Diagnostics main competitors include BibbInstruments, Bio-Gate, PExA, Scandinavian ChemoTech, enVVeno Medical, Sds Optic, Sonendo, Trinity Biotech, Neola Medical, Redsense Medical. |
See public comps similar to Co-Diagnostics
Lists including Co-Diagnostics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




